4.3 Article

Ambulatory Blood Pressure Monitoring: Importance of Sampling Rate and Duration-48 Versus 24 Hours-on the Accurate Assessment of Cardiovascular Risk

期刊

CHRONOBIOLOGY INTERNATIONAL
卷 30, 期 1-2, 页码 55-67

出版社

TAYLOR & FRANCIS INC
DOI: 10.3109/07420528.2012.701457

关键词

Ambulatory blood pressure monitoring; Cardiovascular risk; Hypertension; Methods; Sampling requirements; Sleep-time blood pressure

资金

  1. Ministerio de Ciencia e Innovacion [SAF2006-6254-FEDER, SAF2009-7028-FEDER]
  2. Conselleria de Presidencia, Relacions Institucionais e Administracion Publica, Secretaria Xeral de Investigacion e Desenvolvemento, Xunta de Galicia [PGIDIT03-PXIB-32201PR]
  3. Conselleria de Economia e Industria, Direccion Xeral de Investigacion e Desenvolvemento, Xunta de Galicia [INCITE07-PXI-322003ES, INCITE08-E1R-322063ES, INCITE09-E2R-322099ES, IN845B-2010/114, 09CSA018322PR]
  4. Conselleria de Cultura, Educacion e Ordenacion Universitaria, Xunta de Galicia [CN2012/251, CN2012/260]
  5. Vicerrectorado de Investigacion, University of Vigo

向作者/读者索取更多资源

Independent prospective studies have found that ambulatory blood pressure (BP) monitoring (ABPM) is more closely correlated with target organ damage and cardiovascular disease (CVD) risk than clinic BP measurement. This is based on studies in which BP was sampled every 15-30 min for <= 24 h, without taking into account that reproducibility of any estimated parameter from a time series to be potentially used for CVD risk assessment might depend more on monitoring duration than on sampling rate. Herein, we evaluated the influence of duration (48 vs. 24 h) and sampling rate of BP measurements (form every 20-30 min up to every 2 h) on the prognostic value of ABPM-derived parameters. We prospectively studied 3344 subjects (1718 men/1626 women), 52.6 +/- 14.5 yrs of age, during a median follow-up of 5.6 yrs. Those with hypertension at baseline were randomized to ingest all their prescribed hypertension medications upon awakening or >= 1 of them at bedtime. At baseline, BP was measured at 20-min intervals from 07: 00 to 23: 00 h and at 30-min intervals at night for 48 h, and physical activity was simultaneously monitored every min by wrist actigraphy to accurately derive the awake and asleep BP means. Identical assessment was scheduled annually and more frequently (quarterly) if treatment adjustment was required. ABPM profiles were modified to generate time series of identical 48-h duration but with data sampled at 1- or 2-h intervals, or shorter, i.e., first 24 h, time series with data sampled at the original rate (daytime 20-min intervals/nighttime 30-min intervals). Bland-Altman plots indicated that the range of individual differences in the estimated awake and asleep systolic (SBP) and diastolic BP (DBP) means between the original and modified ABPM profiles was up to 3-fold smaller for data sampled every 1 h for 48 h than for data sampled every 20-30 min for the first 24 h. Reduction of ABPM duration to just 24 h resulted in error of the estimated asleep SBP mean, the most significant prognostic marker of CVD events, in the range of -21.4 to + 23.9 mm Hg. Cox proportional-hazard analyses adjusted for sex, age, diabetes, anemia, and chronic kidney disease revealed comparable hazard ratios (HRs) for mean BP values and sleep-time relative BP decline derived from the original complete 48-h ABPM profiles and those modified to simulate a sampling rate of one BP measurement every 1 or 2 h. The HRs, however, were markedly overestimated for SBP and underestimated for DBP when the duration of ABPM was reduced from 48 to only 24 h. This study on subjects evaluated prospectively by 48-h ABPM documents that reproducibility in the estimates of prognostic ABPM-derived parameters depends markedly on duration of monitoring, and only to a lesser extent on sampling rate. The HR of CVD events associated with increased ambulatory BP is poorly estimated by relying on 24-h ABPM, indicating ABPM for only 24 h may be insufficient for proper diagnosis of hypertension, identification of dipping status, evaluation of treatment efficacy, and, most important, CVD risk stratification. (Author correspondence: rhermida@uvigo.es)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据